EP-1472: Do 4DCT and CBCT imaging doses need to be included in the planning of radiotherapy treatments?  by Rogers, L. et al.
3rd ESTRO Forum 2015                                                                                                                                         S799 
 
joined this inter-comparison. Almost every region of Italy was 
represented. In figure 1, the distribution of the PTV gEUD and 
of the MLDeq2Gy PI are shown. The dot line is the minimum 
PI required value; the spread of the data intra-institution and 
inter-institution is visible. The PI related to the rib max dose 
shows a significant correlation (p=0.01) with the use of 
CyberKnife versus Linac or Tomo. Almost all centers have 
values above the minimum required index but all of them, 
except for CyberKnife, show performances below the 
reference one, indicating a weak consideration of this 
constraint. Otherwise, for the PI of spinal cord max dose, all 
center are above the dot line. Any correlation was found 
between performances and the participants expertise or for 
other technical parameters. 
 
 
Figure 1: distribution of gEUD among the centres and of 
MLDeq2Gy performance index. The dot line is the minimum 
required value. 
 
Conclusions: A notable inter-institutional difference in terms 
of gEUD and general planning strategies was found. For a 
multi-institutional study perspective, detailed dose 
specification and planning strategies based on collaboration 
and discussion are mandatory. 
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Purpose/Objective: 4DCT and CBCT imaging in radiotherapy 
delivers a small priming dose, which is ignored in treatment 
planning, despite evidence that the size and sequence of 
partial fractions affects cell survival1,2. The delay between 
imaging and treatment may be minutes or days for CBCT and 
4DCT respectively. There is a trend towards increasing use of 
these imaging modalities as they enable more accurate 
delivery of therapeutic dose. The biological effect of an 
imaging partial fraction in addition to the therapeutic dose 
on cell survival is uncertain. We report here on the effect of 
an imaging dose prior to a therapeutic dose on cell survival in 
two human cancer cell lines and one normal human cell line. 
The effects are examined for current typical imaging dose 
levels and a projection is made of the effects on cell survival 
of an increase in the imaging dose. 
Materials and Methods: In-vitro clonogenic assays were used 
to obtain experimental data for non-small cell lung cancer 
(NCI-H460), melanoma (MM576) and a normal (HUVEC) cell 
lines. The 4DCT was performed on a Toshiba Aquilon CT with 
a Varian RPM motion management system and the CBCT on a 
6MV proton beam from a Varian Novalis linac with a kV-cone 
beam system. The therapeutic dose D2 was delivered after 
time t using the Varian Novalis. An expression for cell survival 
S was derived using the Lea-Catcheside formalism, with and 
without the imaging dose D1. The effect on cell survival of 
increasing the imaging dose to a projected 10, 20 and 50 cGy 
was modelled. 
Results: For the two human cancer cell lines considered in 
this study, D1 (measured to be 0, 0.60cGy [CBCT] or 14.0 cGy 
[4DCT]) given prior to a D2 (0, 2 or 4 Gy), has no measurable 
effect on cell survival, irrespective of the time delay. The 
theoretical analysis confirmed the experimental findings for 
these imaging doses, that an additional partial fraction dose 
from CBCT or 4DCT is not likely to affect tumour control 
significantly as the cell survival was predicted to decrease by 
2-3% for 4DCT. However, if the imaging dose is increased to 
20 and 50 cGy, it is predicted the clonogenic survival would 
decrease by 6 and 15% respectively for the cancer cell lines. 
This decrease was predicted to be smaller for the normal cell 
line (4 and 6% for 20 and 50 cGy respectively). 
Conclusions: This study indicates that, at the current dose 
levels, it is not necessary to consider the imaging dose from 
4DCT or CBCT in the planning of radiotherapy treatment. 
However, if the imaging dose is increased then imaging dose 
may need to be included in treatment planning. 
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Purpose/Objective: While conventionally fractionated 
radiotherapy (CFRT) has proven ineffective in curing non-
small-cell lung cancer (NSCLC), promising results have been 
obtained with stereotactic body radiotherapy (SBRT) 
employing few high-dose fractions. Extreme 
hypofractionation might however compromise the treatment 
outcome in hypoxic tumours given the reduced possibility for 
reoxygention between fractions. An alternative approach 
